PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
31818450-9	2019	CONCLUSIONS: Early signs of retinal vessel damage in FH patients can be detected and quantified with OCT and OCTA.	CDTA	109-113	low density lipoprotein receptor	Homo sapiens	53-55
30642771-5	2019	The positive rates of tcdA, tcdB, and cdtA/cdtB genes were 62.9%, 63.4%, and 2.8%, respectively.	CDTA	38-42	corneal dystrophy of Bowman's layer type II (Thiel-Behnke)	Homo sapiens	43-47
31415694-7	2019	CONCLUSION: OCTA could be the tool of choice to monitor neovascular response to anti-VEGF treatment in proliferative MacTel 2.	CDTA	12-16	vascular endothelial growth factor A	Homo sapiens	85-89
28512424-15	2017	CONCLUSION: We report on 3 cases of NF1 with choroidal nodules in association with retinal microvascular changes imaged with OCTA.	CDTA	125-129	neurofibromin 1	Homo sapiens	36-39
30308201-9	2019	CONCLUSIONS: This study suggests an association between the SD-OCT and OCTA characteristics of diabetic MAs and the retinal extracellular fluid accumulation at 1 year.	CDTA	71-75	plexin A2	Homo sapiens	63-66
29137019-14	2017	CONCLUSIONS: OCTA is a dyeless, quick, and noninvasive method which allows to detect ischemic changes in DR and might be a useful tool in observing the progress of the disease and the response to anti-VEGF treatment in clinical practice.	CDTA	13-17	vascular endothelial growth factor A	Homo sapiens	201-205
28427360-10	2017	The haplotype analysis of TMEM39A polymorphisms showed that the CGTA haplotype frequency was significantly low in the SLE patients.	CDTA	64-68	transmembrane protein 39A	Homo sapiens	26-33
22219826-1	2011	In the title compound, [Co(C(6)H(4)NO(2))(3)], the Co(III) ion lies on a threefold rotation axis and is in a distorted octa-hedral environment defined by three N and three O donor atoms from three fac-disposed pyridine-2-carboxyl-ate ligands.	CDTA	119-123	mitochondrially encoded cytochrome c oxidase III	Homo sapiens	51-58
27414641-3	2016	Subunits CdtA and CdtC (B-components) allow binding and intracellular translocation of the active CdtB (A-component), which elicits nuclear DNA damage.	CDTA	9-13	corneal dystrophy of Bowman's layer type II (Thiel-Behnke)	Homo sapiens	98-102
25058685-6	2015	Here, we demonstrate that a large isoform of cyclophilin A, the multi-domain enzyme cyclophilin 40 (Cyp40), binds to the enzyme components C2I, Ia and CDTa in vitro.	CDTA	151-155	peptidylprolyl isomerase D	Homo sapiens	84-98
25058685-6	2015	Here, we demonstrate that a large isoform of cyclophilin A, the multi-domain enzyme cyclophilin 40 (Cyp40), binds to the enzyme components C2I, Ia and CDTa in vitro.	CDTA	151-155	peptidylprolyl isomerase D	Homo sapiens	100-105
23061054-3	2012	Several lines of evidence indicate that CdtA and CdtC are required for the optimal intracellular activity of CdtB, although the exact functional roles of CdtA and CdtC remain poorly understood.	CDTA	40-44	corneal dystrophy of Bowman's layer type II (Thiel-Behnke)	Homo sapiens	109-113
23061054-3	2012	Several lines of evidence indicate that CdtA and CdtC are required for the optimal intracellular activity of CdtB, although the exact functional roles of CdtA and CdtC remain poorly understood.	CDTA	154-158	corneal dystrophy of Bowman's layer type II (Thiel-Behnke)	Homo sapiens	109-113
27471600-15	2016	OCTA provides a useful approach for monitoring and evaluating the treatment of intravitreal anti-VEGF for CNV.	CDTA	0-4	vascular endothelial growth factor A	Homo sapiens	97-101
25029374-2	2014	The separate binding and translocation component CDTb mediates transport of the enzyme component CDTa into mammalian target cells.	CDTA	97-101	corneal dystrophy of Bowman's layer type II (Thiel-Behnke)	Homo sapiens	49-53
25029374-3	2014	CDTb binds to its receptor on the cell surface, CDTa assembles and CDTb/CDTa complexes are internalised.	CDTA	48-52	corneal dystrophy of Bowman's layer type II (Thiel-Behnke)	Homo sapiens	0-4
25029374-3	2014	CDTb binds to its receptor on the cell surface, CDTa assembles and CDTb/CDTa complexes are internalised.	CDTA	72-76	corneal dystrophy of Bowman's layer type II (Thiel-Behnke)	Homo sapiens	0-4
25029374-3	2014	CDTb binds to its receptor on the cell surface, CDTa assembles and CDTb/CDTa complexes are internalised.	CDTA	72-76	corneal dystrophy of Bowman's layer type II (Thiel-Behnke)	Homo sapiens	67-71
25029374-4	2014	In acidic endosomes, CDTb mediates the delivery of CDTa into the cytosol, most likely by forming a translocation pore in endosomal membranes.	CDTA	51-55	corneal dystrophy of Bowman's layer type II (Thiel-Behnke)	Homo sapiens	21-25
22090875-2	2011	The Ca(II) atom is octa-coordinated by two O atoms from two water mol-ecules and six O atoms from four acetate ligands.	CDTA	19-23	carbonic anhydrase 2	Homo sapiens	4-10
21315064-8	2011	However, treatment with both angiotensin II and CDTA increased the cell stiffness only slightly compared to solely CDTA-treated cells.	CDTA	115-119	angiotensinogen	Homo sapiens	29-43
21754296-2	2011	The Co(III) atom exhibits an octa-hedral geometry, coordinated by four N atoms from the tris-(2-pyridyl-meth-yl)amine ligand with an average Co-N distance of 1.953 (2) A, and two cyanide C atoms with an average Co-C distance of 1.895 (2) A.	CDTA	29-33	mitochondrially encoded cytochrome c oxidase III	Homo sapiens	4-11
21522824-1	2011	In the title coordination polymer, [Co(C(14)H(16)O(6))(H(2)O)(2)](n), the Co(II) ion, situated on a twofold rotation axis, is coordinated by four O atoms from two 4,4"-[1,4-phenyl-enebis(-oxy)]dibutano-ate (L) ligands and two water mol-ecules in a highly distorted octa-hedral geometry.	CDTA	265-269	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	74-80
15699156-4	2005	Although CdtA and CdtC do not exhibit activity alone, each subunit is able to significantly enhance the ability of CdtB to induce G2 arrest in Jurkat cells; these effects were dependent upon protein concentration.	CDTA	9-13	corneal dystrophy of Bowman's layer type II (Thiel-Behnke)	Homo sapiens	115-119
21579621-3	2010	The coordination at the Co(II) center is best described as distorted octa-hedral with two NO(3) (-) anions serving as bidentate ligands for charge balance.	CDTA	69-73	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	24-30
19448108-1	2009	Rbg1 is a previously uncharacterized protein of Saccharomyces cerevisiae belonging to the Obg/CgtA subfamily of GTP-binding proteins whose members are involved in ribosome function in both prokaryotes and eukaryotes.	CDTA	94-98	GTP-binding protein RBG1	Saccharomyces cerevisiae S288C	0-4
19087203-2	2009	The product of a cdtB/DNAse I chimera formed a heterotrimer with the CdtA and CdtC subunits of the genotoxin, and targeted mutations increased the specific activity of the hybrid protein.	CDTA	69-73	corneal dystrophy of Bowman's layer type II (Thiel-Behnke)	Homo sapiens	17-21
17034038-5	2006	The two characterized structural elements of the aromatic patch and groove on the CdtA and CdtC protein surfaces exhibit high mobility, and free energy calculations show that the heterodimeric complex CdtA-CdtC, as well as the CdtA-CdtB and CdtB-CdtC sub-complexes are less energetically stable as compared to the binding in the tripartite complex.	CDTA	82-86	corneal dystrophy of Bowman's layer type II (Thiel-Behnke)	Homo sapiens	232-236
17034038-5	2006	The two characterized structural elements of the aromatic patch and groove on the CdtA and CdtC protein surfaces exhibit high mobility, and free energy calculations show that the heterodimeric complex CdtA-CdtC, as well as the CdtA-CdtB and CdtB-CdtC sub-complexes are less energetically stable as compared to the binding in the tripartite complex.	CDTA	82-86	corneal dystrophy of Bowman's layer type II (Thiel-Behnke)	Homo sapiens	241-245
17034038-5	2006	The two characterized structural elements of the aromatic patch and groove on the CdtA and CdtC protein surfaces exhibit high mobility, and free energy calculations show that the heterodimeric complex CdtA-CdtC, as well as the CdtA-CdtB and CdtB-CdtC sub-complexes are less energetically stable as compared to the binding in the tripartite complex.	CDTA	201-205	corneal dystrophy of Bowman's layer type II (Thiel-Behnke)	Homo sapiens	241-245
19007994-5	2009	In this study we show that human immunoproteasomes and cathepsin-L can generate octa to undecameric glycopeptides from the MUC1 repeat domain in vitro.	CDTA	80-84	cathepsin L	Homo sapiens	55-66
19007994-5	2009	In this study we show that human immunoproteasomes and cathepsin-L can generate octa to undecameric glycopeptides from the MUC1 repeat domain in vitro.	CDTA	80-84	mucin 1, cell surface associated	Homo sapiens	123-127
17123907-3	2006	The functional toxin is composed of three proteins; CdtB potentiates a cascade leading to cell cycle block, and CdtA and CdtC function as dimeric subunits, which bind CdtB and delivers it to the mammalian cell interior.	CDTA	112-116	corneal dystrophy of Bowman's layer type II (Thiel-Behnke)	Homo sapiens	167-171
16304609-4	2005	CdtA and CdtC possess N- and C-terminal nonglobular polypeptides that extensively interact with each other and CdtB, and we have determined the contribution of each to toxin stability and activity.	CDTA	0-4	corneal dystrophy of Bowman's layer type II (Thiel-Behnke)	Homo sapiens	111-115
15699156-5	2005	Moreover, the combined addition of both CdtA and CdtC increased the ED50 for CdtB >7000-fold.	CDTA	40-44	corneal dystrophy of Bowman's layer type II (Thiel-Behnke)	Homo sapiens	77-81
15699156-10	2005	Furthermore, although CdtB is unable to bind to either CdtA or CdtC alone, it is capable of forming a stable complex with CdtA/CdtC.	CDTA	55-59	corneal dystrophy of Bowman's layer type II (Thiel-Behnke)	Homo sapiens	22-26
15699156-10	2005	Furthermore, although CdtB is unable to bind to either CdtA or CdtC alone, it is capable of forming a stable complex with CdtA/CdtC.	CDTA	122-126	corneal dystrophy of Bowman's layer type II (Thiel-Behnke)	Homo sapiens	22-26
15625307-4	2004	CdtB is the active component, and CdtA and CdtC are involved in delivering the CdtB into the cells.	CDTA	34-38	corneal dystrophy of Bowman's layer type II (Thiel-Behnke)	Homo sapiens	79-83
14688349-2	2004	We now report that the capacity for CdtB to induce G(2) arrest in Jurkat cells is greater in the presence of the other Cdt peptides: CdtA and CdtC.	CDTA	133-137	corneal dystrophy of Bowman's layer type II (Thiel-Behnke)	Homo sapiens	36-40
1826217-2	1991	The Ca2+ binding to troponin C in myofibrils was measured directly by 45Ca using the CDTA-treated myofibrils as previously reported (Morimoto, S. and Ohtsuki, I.	CDTA	85-89	carbonic anhydrase 2	Oryctolagus cuniculus	4-7
11292766-3	2001	Here we demonstrate that purified CdtB converts supercoiled plasmid DNA to relaxed and linear forms and promotes cell cycle arrest when combined with an E. coli extract containing CdtA and CdtC.	CDTA	180-184	corneal dystrophy of Bowman's layer type II (Thiel-Behnke)	Homo sapiens	34-38
9451003-0	1998	CRP interacts with promoter-bound sigma54 RNA polymerase and blocks transcriptional activation of the dctA promoter.	CDTA	102-106	C-reactive protein	Homo sapiens	0-3
9451003-2	1998	Analysis of the sigma54-dependent dctA promoter reveals a novel negative regulatory function for CRP.	CDTA	34-38	C-reactive protein	Homo sapiens	97-100
9451003-3	1998	CRP can bind to two distant sites of the dctA promoter, sites which overlap the upstream activator sequences for the DctD activator.	CDTA	41-45	C-reactive protein	Homo sapiens	0-3
9451003-3	1998	CRP can bind to two distant sites of the dctA promoter, sites which overlap the upstream activator sequences for the DctD activator.	CDTA	41-45	dCMP deaminase	Homo sapiens	117-121
9451003-4	1998	CRP interacts with Esigma54 bound at the dctA promoter via DNA loop formation.	CDTA	41-45	C-reactive protein	Homo sapiens	0-3
9451003-6	1998	CRP is able to repress activation of the dctA promoter, even in the absence of specific CRP-binding sites.	CDTA	41-45	C-reactive protein	Homo sapiens	0-3
9383161-1	1997	Rhizobium melioti DctD activates transcription from the dctA promoter by catalysing the isomerization of closed complexes between sigma54-RNA polymerase holoenzyme and the promoter to open complexes.	CDTA	56-60	dCMP deaminase	Homo sapiens	18-22
8391103-5	1993	We demonstrate that the cAMP receptor protein (CRP) has a repressive effect on the dctA promoter.	CDTA	83-87	catabolite gene activator protein	Escherichia coli	24-45
8391103-5	1993	We demonstrate that the cAMP receptor protein (CRP) has a repressive effect on the dctA promoter.	CDTA	83-87	catabolite gene activator protein	Escherichia coli	47-50
8391103-7	1993	This suggests that the CRP-cAMP complex represses the dctA promoter activity by direct interaction with the DNA.	CDTA	54-58	catabolite gene activator protein	Escherichia coli	23-26
8391103-8	1993	Direct binding of the CRP-cAMP complex to the dctA promoter was confirmed in vitro by gel mobility-shift assays.	CDTA	46-50	catabolite gene activator protein	Escherichia coli	22-25
8391103-9	1993	Sequence analysis of the dctA promoter indicates that the most likely binding sites for CRP are the two confirmed DctD-binding sites.	CDTA	25-29	catabolite gene activator protein	Escherichia coli	88-91
8391103-11	1993	Since in the presence of CRP-cAMP complex the uninduced levels of dctA expression are reduced, whereas induced levels are largely unaffected, such competition appears to be an essential regulatory feature of dctA expression.	CDTA	66-70	catabolite gene activator protein	Escherichia coli	25-28
8391103-11	1993	Since in the presence of CRP-cAMP complex the uninduced levels of dctA expression are reduced, whereas induced levels are largely unaffected, such competition appears to be an essential regulatory feature of dctA expression.	CDTA	208-212	catabolite gene activator protein	Escherichia coli	25-28
1834695-7	1991	Successive CyDTA and CHAPS treatments eliminated both Ca(2+)-induced tension and ATPase activity, which were recovered by the addition of troponin C.	CDTA	11-16	dynein axonemal heavy chain 8	Homo sapiens	81-87
11864825-6	2002	In addition, it has been established that CDT is a tripartite AB toxin in which CdtB is the active "A" subunit and CdtA and CdtC constitute the heterodimeric "B" subunit required for the delivery of CdtB into the target cell.	CDTA	115-119	corneal dystrophy of Bowman's layer type II (Thiel-Behnke)	Homo sapiens	199-203
10946289-5	2000	Analysis of A. actinomycetemcomitans mRNA by RT-PCR suggests that the two small open reading frames upstream of cdtA are coexpressed with cdtA, cdtB, and cdtC.	CDTA	112-116	corneal dystrophy of Bowman's layer type II (Thiel-Behnke)	Homo sapiens	144-148
9515161-7	1998	The carcinoma cell line CarB showed the highest sensitivity to DC-TA-46 (IC50 = 0.8 +/- 0.3 microM).	CDTA	63-68	syntaxin 8	Mus musculus	24-28
2148867-5	1990	When TnC was removed from the skeletal myofibrils by treatment with trans-1,2-cyclohexanediamine-N,N,N",N"-tetraacetic acid (CDTA), the ATPase activity was no longer stimulated by the cations.	CDTA	125-129	tenascin C	Homo sapiens	5-8
2111447-5	1990	Interestingly, alteration of either the microB or E3 site in a 70-base-pair fragment of the IgH enhancer that lacks the binding site for OCTA abolished enhancer activity in lymphoid cells completely.	CDTA	137-141	immunoglobulin heavy chain complex	Mus musculus	92-95
2148867-6	1990	However, after reconstitution of CDTA-treated skeletal myofibril with TnC, the response of ATPase to Ca2+, Cd2+ or Pb2+ was restored.	CDTA	33-37	tenascin C	Homo sapiens	70-73
2148867-6	1990	However, after reconstitution of CDTA-treated skeletal myofibril with TnC, the response of ATPase to Ca2+, Cd2+ or Pb2+ was restored.	CDTA	33-37	CD2 molecule	Homo sapiens	107-110
33235428-13	2020	Conclusion: Microaneurysms as detected by OCTA might serve as a biomarker for a clinical response to anti-VEGF treatment in the short term.	CDTA	42-46	vascular endothelial growth factor A	Homo sapiens	106-110
34722489-12	2021	Conclusions: OCTA may offer a noninvasive and sensitive technique to evaluate the vasculature of both the tumor and the surrounding retina in retinoblastoma.	CDTA	13-17	RB transcriptional corepressor 1	Homo sapiens	142-156
34993212-10	2021	The VEGF level may be associated with the size of the CNV on OCTA (p = 0.043).	CDTA	61-65	vascular endothelial growth factor A	Homo sapiens	4-8
34071730-4	2021	The binding/translocation B-component CDTb facilitates uptake and translocation of the enzyme A-component CDTa to the cytosol of cells.	CDTA	106-110	corneal dystrophy of Bowman's layer type II (Thiel-Behnke)	Homo sapiens	38-42
35405684-9	2022	CONCLUSION: This study suggested that the non-homogenous hyperreflectivity on OCTA could be served as a diagnostic biomarker for putative CNV in CSCR, implying early treatment with anti-VEGF.	CDTA	78-82	vascular endothelial growth factor A	Homo sapiens	186-190
35487962-11	2022	Hence, we proposed that OCTA could reveal retinal and choroidal microvascular changes in MIS-C patients who were completely healthy before the diagnosis of MIS-C.	CDTA	24-28	anti-Mullerian hormone	Homo sapiens	89-92
35060381-5	2022	The comparisons with the ACE2-RBD complex suggested that the presence of octa in the RBD binding site blocked the movements in a loop region at the distal end of the RBD binding interface and promoted the contacts of this loop region with the ACE2 N-terminus helix.	CDTA	73-77	angiotensin converting enzyme 2	Homo sapiens	25-29
35523469-7	2022	OCTA also allowed us to monitor disease progression and monitor response to anti-VEGF therapy.	CDTA	0-4	vascular endothelial growth factor A	Homo sapiens	81-85
35060381-5	2022	The comparisons with the ACE2-RBD complex suggested that the presence of octa in the RBD binding site blocked the movements in a loop region at the distal end of the RBD binding interface and promoted the contacts of this loop region with the ACE2 N-terminus helix.	CDTA	73-77	angiotensin converting enzyme 2	Homo sapiens	243-247
2466307-5	1988	The release of CGRP and substance P induced by electrical stimulation was abolished in Ca2+-free medium containing CDTA and also in normal medium containing the calcium channel blocker cadmium chloride (CdCl2), with no change in the level of the basal release of both peptides.	CDTA	115-119	calcitonin-related polypeptide alpha	Rattus norvegicus	15-19
35106403-5	2022	A marked reduction in the size of the RNV in both eyes was evident on volume-rendered three-dimensional OCTA retinal imaging after the first anti-VEGF injection.	CDTA	104-108	vascular endothelial growth factor A	Homo sapiens	146-150
35106403-6	2022	Conclusion and importance: The ability to directly observe the effect of anti-VEGF injections on a RNV using three-dimensional OCTA was successfully demonstrated.	CDTA	127-131	vascular endothelial growth factor A	Homo sapiens	78-82
2532647-3	1989	Myosin was extracted from myofibrils treated with a solution containing CyDTA, a strong divalent cation chelator.	CDTA	72-77	myosin heavy chain 14	Homo sapiens	0-6
2953710-2	1987	A gel electrophoretic study revealed that all troponin C and about half of myosin light chain 2 were removed from the myofibrils by the CDTA treatment.	CDTA	136-140	myosin regulatory light chain 2, ventricular/cardiac muscle isoform	Oryctolagus cuniculus	75-95
2953710-5	1987	These findings indicate that these characteristic features of divalent cation regulation in the contraction of skeletal and cardiac muscles are determined solely by the species of troponin C. Bovine brain calmodulin hardly activated the ATPase activity of the CDTA-treated myofibrils even in the presence of Ca2+.	CDTA	260-264	calmodulin	Oryctolagus cuniculus	205-215
2953710-6	1987	Excess calmodulin, however, was found to give Ca2+- or Sr2+-sensitivity to the ATPase activity of the CDTA-treated myofibrils.	CDTA	102-106	calmodulin	Oryctolagus cuniculus	7-17
9151-7	1976	Occlusion of the site for Mg2+ can be partially reversed by trans-1,2-diaminocyclohexonetetraacetic acid (CDTA).	CDTA	106-110	mucin 7, secreted	Homo sapiens	26-29
33075509-11	2020	Following the treatment of epithelial cells with C.jejuni or C.coli, IL-8 and TNF-alpha were significantly increased compared to untreated Caco-2 cells, and the highest IL-8 expression was observed in both C.jejuni and C.coli expressing all CDTs (cdtA, cdtB, and cdtC).	CDTA	247-251	C-X-C motif chemokine ligand 8	Homo sapiens	169-173
940269-4	1976	Highly significant and reproducible AC stimulations by these hormones were obtained for the following portions, respectively: DCTa, DCTg and CCTg with PTH; DCTl and CCTl with AVP; DCTg, CCTg and CCTl with isoproterenol.	CDTA	126-130	parathyroid hormone	Oryctolagus cuniculus	151-154
34026789-12	2021	Conclusions: The study showed morphological as well as quantitative changes on OCTA responding to anti-VEGF treatment in mCNV patients, among which vessel junctions might be the most predictive biomarker.	CDTA	79-83	vascular endothelial growth factor A	Homo sapiens	103-107
14215965-6	1964	Although all the chelators tested, when properly supplemented with microelements, allowed excellent growth, diethylenetriaminepentaacetic acid and diaminocyclohexanetetraacetic acid were least affected by additions of heavy metals and are recommended for use at 50 to 100 muM.	CDTA	147-181	latexin	Homo sapiens	272-275
33925984-0	2021	Phenotypic Differences in a PRPH2 Mutation in Members of the Same Family Assessed with OCT and OCTA.	CDTA	95-99	peripherin 2	Homo sapiens	28-33
33681533-8	2021	Conclusions and importance: This case highlights the role of OCTA in diagnosis of choroidal neovascularization in choroideremia as well as its successful management with anti-VEGF injections with long term follow up.	CDTA	61-65	vascular endothelial growth factor A	Homo sapiens	175-179
33495053-7	2021	OCTA also allowed us to monitor disease progression and monitor response to anti-VEGF therapy.	CDTA	0-4	vascular endothelial growth factor A	Homo sapiens	81-85
33474512-8	2021	Results from OCTA revealed that collateral vessels are increased in response to administration of a S1PR1 agonist in a mouse RVO model.	CDTA	13-17	sphingosine-1-phosphate receptor 1	Mus musculus	100-105
32394732-5	2020	After anti-VEGF injection, as early as the 1-day follow-up, the mean selected area and the mean flow area of inflammatory CNV on OCTA were significantly reduced (both P < 0.05) while the average CMT on SD-OCT did not change until the 7-day follow-up.	CDTA	129-133	vascular endothelial growth factor A	Homo sapiens	11-15
32394732-6	2020	OCTA was able to detect the reincrease of capillary density and vessel size predominantly in the second phenotype 14-30 days after anti-VEGF injection.Conclusions: OCTA not only allows for noninvasive detection of inflammatory CNV with a high sensitivity but also facilitates its sequential observation after anti-VEGF treatment.	CDTA	0-4	vascular endothelial growth factor A	Homo sapiens	136-140
32394732-6	2020	OCTA was able to detect the reincrease of capillary density and vessel size predominantly in the second phenotype 14-30 days after anti-VEGF injection.Conclusions: OCTA not only allows for noninvasive detection of inflammatory CNV with a high sensitivity but also facilitates its sequential observation after anti-VEGF treatment.	CDTA	0-4	vascular endothelial growth factor A	Homo sapiens	314-318
32394732-6	2020	OCTA was able to detect the reincrease of capillary density and vessel size predominantly in the second phenotype 14-30 days after anti-VEGF injection.Conclusions: OCTA not only allows for noninvasive detection of inflammatory CNV with a high sensitivity but also facilitates its sequential observation after anti-VEGF treatment.	CDTA	164-168	vascular endothelial growth factor A	Homo sapiens	136-140
32394732-6	2020	OCTA was able to detect the reincrease of capillary density and vessel size predominantly in the second phenotype 14-30 days after anti-VEGF injection.Conclusions: OCTA not only allows for noninvasive detection of inflammatory CNV with a high sensitivity but also facilitates its sequential observation after anti-VEGF treatment.	CDTA	164-168	vascular endothelial growth factor A	Homo sapiens	314-318
32394732-8	2020	OCTA may be a useful tool for diagnosing inflammatory CNV and evaluating the early response to anti-VEGF treatment.	CDTA	0-4	vascular endothelial growth factor A	Homo sapiens	100-104
33246374-6	2022	OCTA detected an abnormal vascular net in the outer retina as well as choriocapillaris, corresponding to type 2 CNV, that reduced following intravitreous anti-VEGF therapy.	CDTA	0-4	vascular endothelial growth factor A	Homo sapiens	159-163
33246374-9	2022	During anti-VEGF therapy for inflammatory CNV-related diseases, OCTA may be useful not only for CNV detection but also for the follow-up of CNV activity.	CDTA	64-68	vascular endothelial growth factor A	Homo sapiens	12-16
32806224-2	2020	Herein, initially octa(3-hydroxy-3-methylbutyl dimethylsiloxy) POSS (Star-POSS) was utilized to initiate the ROP of the epsilon-caprolactone to get octa-arm star-shaped Star-POSS-PCL.	CDTA	18-22	steroidogenic acute regulatory protein	Homo sapiens	69-78
32806224-2	2020	Herein, initially octa(3-hydroxy-3-methylbutyl dimethylsiloxy) POSS (Star-POSS) was utilized to initiate the ROP of the epsilon-caprolactone to get octa-arm star-shaped Star-POSS-PCL.	CDTA	18-22	steroidogenic acute regulatory protein	Homo sapiens	169-178
33062911-10	2020	Although some have suggested early clinical intervention with anti-VEGF injections in any case with fluid and confirmed CNV on OCTA, we describe a subset of AMD patients with SRF who may be better managed by observation.	CDTA	127-131	vascular endothelial growth factor A	Homo sapiens	67-71
32956858-11	2021	In all cases, ORHR on SD-OCT corresponded to ORNV on OCTA.	CDTA	53-57	plexin A2	Homo sapiens	25-28
32438081-2	2020	Serial SS-OCTA imaging showed transient decreases in vascular congestion and exudation after intravitreal anti-VEGF injections.	CDTA	10-14	vascular endothelial growth factor A	Homo sapiens	111-115
32584833-11	2020	Compared to traditional glaucoma staging system judged by VF, the changes of PVD and MVD obtained by OCTA might be a new method to grade the stage of glaucoma.	CDTA	101-105	mevalonate diphosphate decarboxylase	Homo sapiens	85-88
32999681-9	2020	OCTA may be useful in confirming the presence of intraretinal neovascular lesion and monitoring response to anti-vascular endothelial growth factor agents.	CDTA	0-4	vascular endothelial growth factor A	Homo sapiens	113-147
31266775-11	2020	CONCLUSION: OCTA was able to detect similar retinal microvascular changes in patients with USH2A and MYO7A mutations.	CDTA	12-16	usherin	Homo sapiens	91-96
32471149-7	2020	OCTA parameters could represent predictive biomarkers to anti-vascular endothelial growth factor (anti-VEGF) intravitreal response and to help to better understand the physiopathological mechanisms of the RM.	CDTA	0-4	vascular endothelial growth factor A	Homo sapiens	62-96
32471149-7	2020	OCTA parameters could represent predictive biomarkers to anti-vascular endothelial growth factor (anti-VEGF) intravitreal response and to help to better understand the physiopathological mechanisms of the RM.	CDTA	0-4	vascular endothelial growth factor A	Homo sapiens	103-107
31266775-11	2020	CONCLUSION: OCTA was able to detect similar retinal microvascular changes in patients with USH2A and MYO7A mutations.	CDTA	12-16	myosin VIIA	Homo sapiens	101-106
32123082-4	2020	We observe a single molecule of CDTa bound to a CDTb heptamer.	CDTA	32-36	corneal dystrophy of Bowman's layer type II (Thiel-Behnke)	Homo sapiens	48-52
32123082-5	2020	The formation of the CDT complex relies on the interaction of an N-terminal adaptor and pseudoenzyme domain of CDTa with six subunits of the CDTb heptamer.	CDTA	111-115	corneal dystrophy of Bowman's layer type II (Thiel-Behnke)	Homo sapiens	141-145
32123082-6	2020	CDTb is observed in a preinsertion state, a conformation observed in the transition of prepore to beta-barrel pore, although we also observe a single bound CDTa in the prepore and beta-barrel conformations of CDTb.	CDTA	156-160	corneal dystrophy of Bowman's layer type II (Thiel-Behnke)	Homo sapiens	0-4
32123082-8	2020	These structural observations advance the understanding of how a single protein, CDTb, can mediate the delivery of a large enzyme, CDTa, into the cytosol of mammalian cells.	CDTA	131-135	corneal dystrophy of Bowman's layer type II (Thiel-Behnke)	Homo sapiens	81-85
32231830-17	2020	Conclusion: It is possible that OCTA can be used for detailed evaluation of CNV associated with ODD, response to anti-VEGF treatment, and peripapillary and macular vascular density.	CDTA	32-36	vascular endothelial growth factor A	Homo sapiens	118-122